Huang Wei-Zhao, Fu Jian-Hua, Hu Yi, Zhang Xu, Yang Hong
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ai Zheng. 2006 Oct;25(10):1303-6.
BACKGROUND & OBJECTIVE: Although adjuvant chemo-therapy is a component of combined therapy for esophageal cancer, whether it can effectively improve the survival rate remains controversial. This study was to evaluate the efficacy of adjuvant chemotherapy on advanced localized esophageal carcinoma after radical surgery.
Randomized clinical studies on surgery plus chemotherapy and surgery alone for patients with localized esophageal carcinoma from Jan. 1995 to Jun. 2005 were selected from CBMDisc, CNKI, and PubMed databases. RevMan4.2 software was used for meta-analysis.
Seven reports were included in the meta-analysis and a total of 864 patients had been included. Compared with that of the patients underwent surgery alone, the 3-year survival rate of the patients underwent surgery plus adjuvant chemotherapy was significantly elevated, with the combined relative risk (RRs) of 0.83 (P=0.009, 95% confidence interval = 0.71-0.95).
Postoperative adjuvant chemotherapy can improve the 3-year survival rate of the patients with esophageal carcinoma.
尽管辅助化疗是食管癌综合治疗的一个组成部分,但它能否有效提高生存率仍存在争议。本研究旨在评估辅助化疗对局部晚期食管癌根治术后患者的疗效。
从中国生物医学文献数据库(CBMDisc)、中国知网(CNKI)和PubMed数据库中选取1995年1月至2005年6月期间关于局部食管癌患者手术加化疗与单纯手术的随机临床研究。采用RevMan4.2软件进行荟萃分析。
荟萃分析纳入7篇报告,共864例患者。与单纯手术患者相比,接受手术加辅助化疗患者的3年生存率显著提高,合并相对危险度(RRs)为0.83(P = 0.009,95%置信区间 = 0.71 - 0.95)。
术后辅助化疗可提高食管癌患者的3年生存率。